SCHEDULE 13G/A: Rock Springs Capital Affiliates Disclose 5.72% Stake in Travere Therapeutics

Rock Springs Capital Management LP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 5.72% of Travere Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard, and Kris Jenner collectively reported beneficial ownership of 4,973,649 shares of Travere Therapeutics, Inc. common stock.
• This aggregate amount represents 5.72% of the outstanding common stock of Travere Therapeutics, Inc.
• The reporting persons hold shared voting and shared dispositive power over all 4,973,649 shares.
• The filing is an Amendment No. 1 to a previously filed Schedule 13G, indicating an update to their ownership disclosure.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Travere Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest positive or negative sentiment regarding the issuer's performance or outlook.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, which mitigates the risk of activist investor intervention from this specific filing.

Future Outlook

This document does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction, as it is solely a beneficial ownership disclosure.

Industry Context

This Schedule 13G filing indicates a significant passive investment by Rock Springs Capital, an investment firm specializing in healthcare and biotechnology, in Travere Therapeutics, a biopharmaceutical company. Such filings are standard disclosures for institutional investors crossing a 5% ownership threshold, providing transparency on major shareholders within the industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake in the company, which can influence investor perception and liquidity.

Key Dates

Keywords

Travere Therapeutics, Rock Springs Capital, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional ownership, investment management, biotechnology, pharmaceuticals